Good afternoon, everyone, and welcome back. I am joined now by James McBrayer, the effervescent CEO of Cyclopharm. James, thanks for joining us this afternoon.
Good to be here.
Good on you. For those of you who have followed Cyclopharm for a little while, Technegas remains the standard of care for functional lung imaging in most countries around the world. The product is deployed in 60 or more countries, and that includes now the U.S., where the commercial launch happened a couple of years ago. We are going to focus on that market in our discussions this afternoon. Technegas now has 84 systems installed across the U.S., and that is barely scratching the surface, I think it is fair to say, James. Nevertheless, revenues are still building nicely. You had another encouraging quarter in the September quarter, and it is really coming now into the very busy part of the year with everyone back at their desk in the U.S. following the summer break.
It is really with great excitement that we approach the next 12 months or so of the company's development.
Thanks, John. I mean, you hit certainly a lot of the high points there. 67 countries around the world outside the U.S. where we are established, we are 85% market share. We believe that market share will continue through in the U.S. We see the U.S. market, just in what we are best known for, in diagnosing pulmonary embolism, to be a $180 million market. Beyond PE, the true leverage of Technegas, which is a true functional ventilation imaging agent, we see that market greater than a billion dollars.
Okay, James. Let us just take it back a step. For the benefit of people who are perhaps new to the story, can you give us a couple of minutes just on what is Technegas and how it is deployed and why it is used?
There is nothing like Technegas. Technegas is a true functional ventilation imaging agent in that anywhere that oxygen goes in your lungs, Technegas is deposited there, and the clinicians can then take an image of where that oxygen was deployed in the lungs. The American Thoracic Society used to say, "If you cannot breathe, nothing else matters." We show that at the fundamental level of where oxygen is deployed. From that, the technology that is used to leverage off of that information is growing rapidly, leveraging off of AI. In fact, we are probably more relevant today than we ever have been. Technegas is a nano-sized particle. It is created on-site at the point of care at the hospital. It has operational advantages for the department. It has clinical advantages compared to its competing products.
That is why it is no wonder that we expect that 85% market share to carry through into the U.S.
Yeah. James, you have a long shopping list of very high-quality academic medical institutions who have become the first adopters. I think you are in at least 50% of the top 20 now. Correct me if I am wrong there. I am sure you will. The take-up rate has been very, very encouraging. That is a great feather in your cap.
John, you are quite right. Of the top 200 hospitals in the country, we are at a quarter of those now.
Okay.
You mentioned the top 20, the honor roll. At our update, we had half of those. We are engaged with all of the 20, but we had half of those at the last Q3, and I can tell you we have signed two more of those.
Stanford was one of our first ones.
Okay.
The latest ones, we have signed the Cleveland Clinic. We are putting in three installations with the Cleveland Clinic, and we signed one of the top 20. It is a Southern California hospital just the other day.
James, you have obviously gotten out into the market and spoken to plenty of clinicians who are using the product now and in increasing volumes. What are they telling you about the quality of the images that they are able to get now? How is this changing patient outcomes, do you think?
Well, I think one of the things that we are going to probably highlight is certainly the guidelines. There were some guidelines that were released just only a few weeks ago, really, in the middle of summer. It highlights the advantages of Technegas from a clinical and an operational point of view. Our point of difference, certainly with these nuclear medicine products that we displace and why we have 85% of the market share, is that we deliver a consistency, a clinical consistency with patients that they know they are always going to get the optimal image from that procedure. So much so, what has happened over the course of what we are seeing in the marketplace now is the rates of indeterminate, i.e., when they take a scan of these competitive products, they cannot actually get an outcome because of the quality of the images that they are receiving. Technegas eliminates that.
In fact, we have seen, and these are referenced in these guidelines that we will probably talk a little bit more about, they are getting less than 5% indeterminate. That has a huge flow-on effect, not only for the patient, because they know if they have got this disease state or not, but it also has an economic benefit to the hospitals in that they are not having to repeat procedures or put them on a therapy like anticoagulants that have their own risks.
Yeah. Pulmonary embolism, let's talk about that for a minute, because that's the primary condition for which Technegas is used. Can you take a few moments to describe what is PE? It's a lethal condition. I've had a couple of friends, people who I've known who have passed away from PE, blood clots, started in the legs, long travel flights. Eventually these clots work their way up into the lungs. This is a potentially deadly situation that many patients are facing here. Explain the depth of the problem.
John, you're right. Very often, a pulmonary embolism or a blood clot in the lung originates from somewhere else. It could be a post-surgical intervention. That's why a lot of the deaths in hospitals, up to 7%, are coming from a pulmonary embolism. You quite rightly said that during flights, people develop deep vein thrombosis.
Yeah.
Whilst that's uncomfortable, it's not necessarily lethal. It's when those clots break off and they either go to your brain, your heart, or your lungs.
Mm. Now, the conventional method of diagnosis of these is through CT, but obviously the nuclear medicine piece is indicated for folks who are contraindicated for CT. This is a nice big market for you. Let's talk about the size of this market, and also if you can start to touch there on the beyond PE piece, and the other applications that-
Sure
— Technegas is now being used for.
John, when I first started out, my background's in nuclear pharmacy. When I first started out, it wasn't CT that started things. What happened, I guess, along the way is, planar imaging was kind of the basis of how people were imaging, when I first started out in nuclear medicine, and then CT came on board. Rightly so, the clinical outcomes from CT outweighed some of the planar. What's happened is technology's evolved, right? What we're seeing now in nuclear medicine when you add three-dimensional imaging, which is called SPECT and SPECT/CT, we exceed the clinical outcomes with CT in just about every category, and particularly the negative predictive value on that in every case. We also show a better clinical outcome compared to CT, at a much, much lower radiation dose.
Yeah.
You quite rightly said, though, that CT is usually the first line. Very often, certainly in the U.S., it's the first line, and nuclear medicine is considered to be if it's contraindicated, if they have an allergy to contrast, if they're pregnant, and if there's the concern about the radiation dose. That certainly directs people towards nuclear medicine. Where we're seeing, though, is the clinical outcomes at the lower radiation dose, we're starting to see a shift back from CT towards nuclear medicine.
Oh, okay. Because of what's driving that, James, that last
Well, I think it's the technology, John.
Yeah
When sites start to employ the SPECT and SPECT/CT, where you get both function and anatomy, you get the best outcomes for the patient.
Yeah.
CT, beautiful structural images, absolutely. But they all, CT and all of these anatomical images, they leverage their information off of anatomy and algorithms.
There's nothing more fundamental than showing exactly where oxygen is delivered into the body. That is the fundamental dataset—
Yeah
—that all of these algorithms can actually leverage off of, not this massive radiation dose that they're passing through the patients. We're starting to see different applications, as you rightly put it. I'm happy to jump into that if you want.
Yeah, let's spend a minute on that. Then I want to come back to talk about the guidelines update that happened recently as well.
Great.
Let's spend a minute on the other applications, and there are many of them, for monitoring of therapies and also for transplant patients and so on. There's a multitude of things we can talk about on this topic alone.
I guess where we want the audience to understand is, we're replacing existing technology in the U.S. We're not trying to create a different type of platform. If they just transfer what they're doing in the U.S. with Technegas, they're going to have better patient outcomes and economic outcomes, probably for their institutions. That's worth $ 180 million to us.
Right? Just on that basis. Part of that is the evolution of the technology and embracing that in using this three-dimensional imaging. Two-dimensional imaging is outdated, and I often refer to the technology that is probably being used mostly in the U.S., it is trying to compare Sputnik to SpaceX. Nuclear medicine is at SpaceX now, right?
Yeah.
They are still practicing in many locations the way that it was even before my time when I first started out in nuclear medicine in the 1980s. With that technology, John, where we can show true function, absolute true function, where then you overlay structure and function, and then you overlay that, this analytical information that you can extract from the core true functionality that our product delivers, it can be applied to a whole host of disease states with respiratory medicine.
Yeah.
I mean, that is the fundamental aspect of respiratory medicine. It is getting oxygen into the patient's body, and we show that.
Yeah.
We show that. Without algorithms, without analysis, Technegas shows that.
Yeah, it's straight up . Now, James, let's talk about the-
Sorry, John. You were talking about the applications.
Yeah.
Right now, we're seeing applications in asthma, COPD, lung transplant. Anything that you can possibly think of, there's probably a publication out there with Technegas, and I think that's probably an important. We have clinical data that absolutely supports the use of Technegas in a host of these disease states, and that's been a body of work that's been developed over a couple of decades.
Yeah. It's certainly been progressing, and for years it was being developed in Canada and France and numerous other countries around the world. But in the U.S., I think it's fair to say that that has taken a step up to the next level in terms of the R&D work that's going on behind it. James, let's talk about the society guidelines for use of this product now.
Yeah. John, I have been around in nuclear medicine for quite some time in healthcare, and guidelines do not happen every so often. In the U.S., the last time they updated their guidelines was 2012.
Yeah.
It was a long time coming, and I think they waited for Technegas, actually.
Guidelines are basically a Bible, if you will. It is how you practice the gold standard in delivering these types of procedures. The guidelines that were released in the U.S., and it was in collaboration with the Society of Nuclear Medicine in the U.S., the European Association of Nuclear Medicine, the Australian and New Zealand Society of Nuclear Medicine, and the American College of Nuclear Medicine. It is the first time that an international guideline like that has ever been put together for lung imaging. The other point I would like to make about that was significant, it used to be about diagnosing pulmonary embolism. These guidelines actually go beyond that and say pulmonary scintigraphy or lung imaging, and it starts to talk about these other applications. It is becoming mainstream, John.
I think the importance of this is that, it is one thing for a CEO to say he loves his product. It is one thing for the occasional doctor that supports it, an imaging platform, and even a clinical paper from here and there is important—
Yeah
—but there's nothing like guidelines. It's the consensus of thousands of inputs to actually come out with, and Technegas is named as the agent of choice—
Yeah
—in the U.S.
The U.S. hospital system takes the guidelines incredibly seriously, because everybody knows how litigious healthcare is in the U.S. If you miss a diagnosis because you don't stick to the guidelines, you can find yourself in hot water as a clinician personally, let alone the hospital itself. So, that is a very significant factor in driving this adoption that we're seeing now.
You're absolutely right. Again, we had a tremendous amount of clinical support in the U.S., even from when they were lobbying the FDA to help expedite our approval process.
Yeah.
We had clinicians in the Society of Nuclear Medicine lobbying on our behalf, and that's great from the clinician's point of view. But when you get beyond that, when you get to committee level, when you get to accountants, when you get to people at the administration level, you're not just asking the clinicians to support something. You've got a guideline, the gold standard in which that they've got to back or be in, I guess, breach.
Yeah. Look, James, those guidelines were a nice segue into our next topic, which I want to switch to now and talk about the actual adoption rate. Because once those guidelines came out a few months ago, it's fair to say that there was a step change in the rate of adoption. You've gone from something like 40 devices deployed in March this year through to now 84. While it took you 15, 18 months to get to the 44, you've more than doubled that now, or nearly doubled that in the last few months. That's really put or lit a fire under the adoption rate.
I think we're just starting to see the adoption rate, John. Everything has a little bit of a lag time, and so those ones that we got across the line that we updated our shareholders on, they really didn't have the opportunity to see the traction. What we are seeing, though, is we are seeing movement, and we've been very open with our pipeline at the various stages of where all the deals are—
Yeah
—that we're working on. We are seeing an increase in conversion. We are seeing a movement that's going faster now—
Yeah
—than we saw before. We are also seeing from a prospecting point of view, John, and prospecting is either we are going out with proactively engaging sites that we have not engaged before, or we are also seeing a great number of incoming calls based on the response to the guidelines. The other great thing too, John, is that they are only online right now. They actually have not been published in print form yet. They are out there, and we can certainly But those are coming out in, I guess, this month and next month in two different journals that the Society publishes. So, the traction is still there. We have had engagement at local level to get the word out, but we actually have not seen the real benefit yet of the guidelines. That is probably going to come more towards in the beginning of next year.
Okay. So, that is plenty to look forward to. James, let us talk about the commercial aspects of the rollout now in terms of revenue per patient and how the business model looks for the adoption of Technegas in the U.S. and why that is different to the rest of the world.
Yeah. One of the things that when we got it approved with the FDA, and this is an important point to make, we are a combination product. We are both a drug and a device. In that, there is also a service component-
Yeah
—in that component as well. We wanted to make sure that our systems were always going to be maintained and supported, and it also got us closer to the customer as long as we main kind of custody of those systems. The U.S. is different. We do not sell the systems. It is like a lease basis, so it is an annual fee, a fully serviced unit. Really what we want is getting our technology out to help as many patients as possible, but we really make our money off of the per-patient consumables. That is-
Yeah
—really where our motivation is. Get it out as quickly as it can. Try to avoid the capital expenditure discussions, although it would be modest compared to some of the multimillion-dollar expenditures that they do in these departments. But it takes that off the table. From there, it is just about an annuity stream. Every system that we install, it just keeps delivering revenues for us at very high margins in the U.S.
Yeah. You get something like, you get a AUD 7,000 installation fee, then there is an annual maintenance fee. You have a series of upfront fees and plus the first box of consumables. You are looking at around about AUD 22,000, AUD 23,000 at the installation of every single machine?
That is about right, yeah. We get $225 per patient. That is what we are charging in the U.S. We sell them in sets of 50. When you add installation, the annual fee, and the first box of 50, that gets you around that $24,000, $25,000. Then it is all about the renewal of the consumables thereon and the annual fee that goes along with it.
Yeah. That model seems to be working quite nicely with the client base. Like I say, 84 systems installed at the moment. How is the fourth quarter of this year shaping up and as we head into next calendar year?
We've got great momentum, and people saw where we were in the various stages of the pipeline. We are converting those. We've got great traction, and we are absolutely leveraging these guidelines. You fight Christmas and Thanksgiving in the U.S. a little bit, but I think other than that, the U.S. continues to work, and we're driving a slightly different strategy that we used to do. It used to, you do this step and you do this step. What we're doing right now, because these sites, from a clinical point of view, are already convinced that this is where they're going, we're able to now to kind of skip a sequential step and bring it forward by doing the electrical installation for the unit. As soon as the ink is not even dry, we can start to move towards installations.
That was a great example, University Hospitals Cleveland, where we were working with them, 11 sites all in one go, and as soon as the contract was done, we'd had all that pre-work done, and we rolled that out within a couple of weeks.
Yeah. Okay. Let's talk about the VA, James, because you are an accredited supplier to the VA and also the Department of Defense. You've got a small number of systems already in VA hospitals. What's the potential of that contract for you?
Yeah. Unlike the regular hospitals out there where we typically have three-year contracts, we actually were able to secure a five-year contract with the VA. Already we've got nine locations. We've got some more VA hospitals coming on stream on this quarter. Some pretty notable locations as well, and from the military point of view, where we've got Walter Reed Hospital, I think that's very well known, and we've got the Brooke Army Medical Center, which is the largest military hospital, and we've also added the NIH. We just see that growing, John. We're engaged with more and more VA hospitals. It's an important sector for us for a lot of reasons, of course, but there's some great growth. I've even got a call in with the VA this week. We're starting to see a step change, particularly now that the guidelines.
And I think this call that is coming up is saying, "Okay, right. We have got some great traction. We are moving forward throughout the military and the VA. You have got the guidelines now. Now we need to take this up another level.
Yeah. So we have talked about the academic medical centers. They are certainly very strong early adopters. Talked about the government sector. That certainly sounds like it is going very well. But in the middle, you have got this very, very large segment, which I will broadly call the integrated delivery networks, or the IDNs, and they are certainly a huge market in the U.S. What is your expectation for them going forward? Because they have been laggards in adoption, I think it is fair to say.
Well, I think, even John, those 84 that you are talking about, we have plenty that fit in there. Of course, we have got Emory and Massachusetts General and Stanford and UAB, and Northwestern is doing great. But we do have quite a number of these community, they call them community-based hospitals. I just got back from the U.S. on Saturday, and probably half my stops with my salespeople that I was riding shotgun with, they were all community-based.
Okay.
About half of them.
Yeah. Okay.
A couple of the top 20, I'll throw that one in there too, that we're pretty close to, and a couple more that we're working on to get another top 20 sites on board as well.
Yeah. So at your last update, you had 34 sites that were contracted, so signed, sealed, but not yet delivered. So, what's your expectation then for the timing on those installations? Because that'll sort of get you very quickly to in excess of 100 devices. That's a bit of a milestone. Then from there, I expect the second 100 will be significantly faster.
Yeah. John, that's true. I think once it hits contract review, you can count it. It's just a matter of the installations, working through facilities and getting some of the electricals that we couldn't get done before that point in time. So you can count those. But I think what's also important for people to understand is what we're seeing is that land and expand in two different ways, where we get into a system, and I think Massachusetts General is a great example. We landed there, and then we went to Brigham and Women's, and now we're at Salem. We landed at one location at Emory, and then we expand to four additional locations. We've done that time and time again. In fact, when you look at the overall number, if we go back to over 50% is that land and expand.
Yeah.
Then what happens, you get the sites there, then you get other hospitals, whether it be community, and we have seen that in the Dallas area. The visit I just made, we are growing in the Dallas area because we started at some of the major sites there.
Okay. Look, James, we are just about-
UT Southwestern, isn't it?
Yeah.
Yeah.
We are just about out of time, but I just wanted to finish with a quick summation of your financials. You are headed towards AUD +30 million in revenues for FY 2026, your December year-end. Had a pretty good first half. The update at September was encouraging. So that revenue number continues to build nicely. You got plenty of cash in the bank, but you are still not quite at cash flow positive, but it is sort of now on the horizon. Is that a fair summation?
Yeah. For the first three quarters, we booked AUD 25.9 million, and usually we are always a great fourth quarter company.
Yeah.
But that being said, we have reached peak cash burn.
Yeah
Last half 2025, and we are calendar year when I am referencing that. We were at AUD 1.8 million a month cash burn. The first half of this year, we were at AUD 1.3 million. At Q3, we had gotten down to AUD 900,000, and that trend continues.
Yeah.
It continues because the math is not hard, right?
Yeah.
You got these high margin returns that we are making on these consumables at every installation. It just drops to the bottom line, John.
Yeah. It is immensely scalable. So, it is a great outcome, and it is fantastic that you have managed to keep it in-house rather than having to appoint an external distributor. James-
Nobody loves your product like you love your product, John.
Yeah. Exactly. I have heard that many times. James, thank you for your time today. It has been a great run through. Best of luck for the fourth quarter, and I look forward to hearing from you in the not too distant future with your December quarter revenues. So thank you very much.
Thanks for the opportunity, John.
Okay. We are going to go to a short break rather, and then I think Marty's back with Scott Kirkland from EMVision. Thank you very much.